User:Mr. Ibrahem/Evinacumab

Evinacumab, sold under the brand name Evkeeza, is a medication used to treat homozygous familial hypercholesterolemia (HoFH). It is used in those who are at least 12 years old; however, effects on heart disease and life expectancy is unclear as of 2022. It is given by injection into a vein.

Common side effects include the influenza-like illness, dizziness, runny nose, and nausea. Other side effects may include anaphylaxis. Use in pregnancy may harm the baby. It is a monoclonal antibody that binds to and blocks angiopoietin-like protein 3 (ANGPTL3), resulting in faster break down of fats.

Evinacumab was approved for medical use in the United States and Europe in 2021. In the United States it costs about 450,000 USD per year as of 2022.